Soheil Meshinchi
#163,346
Most Influential Person Now
Researcher
Soheil Meshinchi's AcademicInfluence.com Rankings
Soheil Meshinchicomputer-science Degrees
Computer Science
#9583
World Rank
#10059
Historical Rank
Computational Linguistics
#2339
World Rank
#2362
Historical Rank
Machine Learning
#4235
World Rank
#4284
Historical Rank
Artificial Intelligence
#4585
World Rank
#4647
Historical Rank
Download Badge
Computer Science
Why Is Soheil Meshinchi Influential?
(Suggest an Edit or Addition)Soheil Meshinchi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update. (2011) (792)
- Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. (2001) (509)
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. (2010) (475)
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. (2012) (454)
- FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. (2001) (439)
- The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (2017) (416)
- Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. (2004) (415)
- Clinical implications of FLT3 mutations in pediatric AML. (2006) (395)
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) (373)
- Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. (2014) (321)
- Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia (2005) (256)
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. (2012) (238)
- Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. (2006) (233)
- FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. (2003) (229)
- Relationship of the 90-kDa murine heat shock protein to the untransformed and transformed states of the L cell glucocorticoid receptor. (1987) (217)
- Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia (2009) (216)
- The incidence and clinical significance of nucleophosmin mutations in childhood AML. (2007) (206)
- Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. (2009) (196)
- The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (171)
- Identification of genes with abnormal expression changes in acute myeloid leukemia (2008) (167)
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. (2010) (165)
- AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia (2012) (162)
- Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex. (1990) (155)
- Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. (2003) (149)
- Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia (2015) (137)
- C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. (2010) (131)
- Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. (2016) (121)
- Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. (2004) (121)
- Structural and numerical variation of FLT3/ITD in pediatric AML. (2008) (118)
- Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group (2011) (116)
- Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. (2006) (115)
- PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group (2004) (115)
- Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. (2015) (109)
- Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study (2010) (105)
- CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. (2016) (101)
- NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern (2013) (100)
- A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies (2006) (100)
- CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. (2017) (100)
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. (2008) (98)
- Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. (2004) (90)
- NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. (2014) (86)
- Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. (2010) (81)
- Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor. (1991) (80)
- Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia (2013) (76)
- Interaction of the glucocorticoid receptor with the Mr 90,000 heat shock protein: an evolving model of ligand-mediated receptor transformation and translocation. (1989) (75)
- Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. (2006) (75)
- Genomic subtyping and therapeutic targeting of acute erythroleukemia (2019) (73)
- Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. (2017) (71)
- Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients (2013) (70)
- Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia (2003) (70)
- Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group (2020) (68)
- Sample processing obscures cancer-specific alterations in leukemic transcriptomes (2014) (68)
- Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. (2016) (66)
- Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia (2004) (66)
- WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. (2010) (63)
- Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. (2004) (61)
- Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. (2003) (60)
- Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. (2017) (57)
- Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia (2015) (56)
- Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants. (2015) (56)
- MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors (2013) (55)
- The role of sulfhydryl groups in permitting transformation and DNA binding of the glucocorticoid receptor. (1987) (52)
- FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. (2006) (51)
- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy (2013) (50)
- CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. (2016) (50)
- Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3‐ITD status: a report from the Children's Oncology Group (2014) (48)
- Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2015) (47)
- Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report (2013) (47)
- Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. (2007) (46)
- Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. (2011) (45)
- Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia (2019) (45)
- FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group (2012) (45)
- Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia (2009) (43)
- Elimination and reconstitution of the requirement for hormone in promoting temperature-dependent transformation of cytosolic glucocorticoid receptors to the DNA-binding state. (1990) (41)
- Molecular targets in acute myelogenous leukemia. (2003) (41)
- High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group (2015) (38)
- FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia (2001) (38)
- DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group (2008) (38)
- Demonstration that the 90-kilodalton heat shock protein is bound to the glucocorticoid receptor in its 9S nondeoxynucleic acid binding form. (1987) (38)
- Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. (2018) (37)
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia (2016) (37)
- High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. (2010) (37)
- High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group (2013) (36)
- Prevalence and prognostic significance of Flt 3 internal tandem duplication in pediatric acute myeloid leukemia (2000) (36)
- MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia (2017) (36)
- Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group (2017) (35)
- A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group (2016) (34)
- Prognostic Factors in Pediatric Acute Myeloid Leukemia (2010) (34)
- Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML (2014) (33)
- AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia (2014) (32)
- FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. (2013) (31)
- BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group (2014) (31)
- Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group (2011) (31)
- CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. (2020) (30)
- Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia (2019) (29)
- Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. (2015) (28)
- Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia (2017) (28)
- Evidence that the endogenous heat-stable glucocorticoid receptor stabilizing factor is a metal component of the untransformed receptor complex. (1988) (27)
- Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets. (2012) (26)
- Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype. (2018) (26)
- CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group. (2021) (26)
- Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. (2007) (25)
- Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. (2013) (25)
- ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial (2019) (25)
- Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. (2018) (25)
- A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML (2017) (24)
- Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study (2018) (24)
- MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group (2010) (24)
- Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia (2018) (24)
- Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia (2020) (23)
- miR‐155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group (2016) (22)
- St. Jude Cloud-a Pediatric Cancer Genomic Data Sharing Ecosystem. (2021) (21)
- Structural and functional Alterations of FLT 3 in Acute Myeloid Leukemia (2009) (21)
- Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531 (2017) (21)
- The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: Report from the Children's Oncology Group (2014) (21)
- COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML) (2008) (20)
- Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531 (2021) (20)
- Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031 (2019) (20)
- High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group (2014) (19)
- Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. (2018) (19)
- Prevalence and prognostic implications of WT 1 mutations in pediatric acute myeloid leukemia ( AML ) : a report from the Children ’ s Oncology Group * (2010) (19)
- Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2013) (18)
- Selective molybdate-directed covalent modification of sulfhydryl groups in the steroid-binding versus the DNA-binding domain of the glucocorticoid receptor. (1990) (18)
- Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative (2015) (18)
- Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2017) (18)
- Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling (2018) (17)
- Receptor tyrosine kinase alterations in AML - biology and therapy. (2010) (17)
- Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. (2017) (17)
- Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group (2015) (17)
- The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia (2013) (17)
- Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia (2019) (17)
- Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse (2004) (16)
- AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (16)
- Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia (2014) (16)
- Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. (2016) (16)
- Transcriptome Profiling of Pediatric Core Binding Factor AML (2015) (15)
- The clinical and biological characteristics of NUP98-KDM5A pediatric acute myeloid leukemia (2020) (15)
- Development and validation of a single‐cell network profiling assay‐based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group (2013) (15)
- Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long‐term voriconazole (2015) (15)
- NUP98/JARID1A Is a New Recurrent Genetic Abnormality in Pediatric Acute Megakaryoblastic Leukemia with a Distinct HOX -Gene Expression Pattern (2012) (15)
- Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. (2009) (15)
- Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. (2017) (15)
- Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2020) (15)
- Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031 (2012) (14)
- Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531 (2010) (14)
- Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531 (2013) (13)
- The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group (2016) (13)
- Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531 (2016) (13)
- Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials (2017) (13)
- Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group (2008) (13)
- Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2015) (13)
- Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines (2016) (13)
- Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia. (2020) (12)
- Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia (2022) (12)
- Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. (2021) (12)
- The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. (2015) (12)
- Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 (2015) (11)
- Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. (2021) (11)
- Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report (2013) (11)
- CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children’s Oncology Group Report (2014) (11)
- CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group (2021) (11)
- The relationship between glucocorticoid receptor binding to Hsp90 and receptor function. (1990) (10)
- Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia (2021) (10)
- Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031 (2022) (10)
- Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia (2021) (10)
- Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group. (2010) (10)
- Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial. (2005) (9)
- Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children (2019) (9)
- CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. (2019) (9)
- Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study (2012) (9)
- CD 33 Expression and Its Association With Gemtuzumab Ozogamicin Response : Results From the Randomized Phase III Children ’ s Oncology Group Trial AAML 0531 (2018) (9)
- Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. (2017) (8)
- CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents (2019) (8)
- Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3/ITD Mutations (2018) (8)
- Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia (2003) (8)
- Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group (2010) (8)
- Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study (2019) (8)
- Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group (2013) (8)
- Purification of the endogenous glucocorticoid receptor stabilizing factor. (1991) (8)
- Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals (2016) (8)
- TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group (2010) (8)
- Transplantation for AML in children. (2012) (7)
- Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531 (2011) (7)
- Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study (2019) (7)
- Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML. (2011) (7)
- Elevated expression of the AF 1 q gene , an MLL fusion partner , is an independent adverse prognostic factor in pediatric acute myeloid leukemia (2004) (7)
- Translating Discovery into Cures for Children with Cancer Childhood Cancer Research Landscape Report (2016) (7)
- Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. (2019) (7)
- Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (2019) (7)
- Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. (2020) (7)
- Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531 (2014) (7)
- Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group (2019) (7)
- Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative (2016) (6)
- Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. (2020) (6)
- Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML (2021) (6)
- CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients (2018) (6)
- FLT 3 internal tandem duplication in CD 34 / CD 33 precursors predicts poor outcome in acute myeloid leukemia (2006) (6)
- High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study (2008) (6)
- BIRC 5 ( Survivin ) Splice Variant Expression Correlates With Refractory Disease and Poor Outcome in Pediatric Acute Myeloid Leukemia : A Report From the Children ’ s Oncology Group (2014) (6)
- Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children’s Oncology Group report. (2017) (5)
- Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML (2019) (5)
- Hematopoietic cell transplantation in high-risk childhood acute myelogenous leukemia. (2013) (5)
- Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group. (2020) (5)
- Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile (2019) (5)
- Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse. (2007) (5)
- Comparison of Multidimensional Flow Cytometry With Standard Morphology for Evaluation of Early Marrow Response in Pediatric Acute Lymphoblastic Leukemia (2001) (5)
- Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2019) (5)
- Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate (2018) (5)
- Sub-Morphologic Evidence of Disease Prior to Stem Cell Transplantation Correlates with Inferior Post Transplant Outcome in Childhood Acute Myeloid Leukemia. (2009) (5)
- Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens (2017) (5)
- Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study (2022) (5)
- “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors (2022) (4)
- Gene Expression Profiling to Predict Viridans Group Streptococcal and Invasive Fungal Infection in Pediatric Acute Myeloid Leukemia: A Brief Report from the Children's Oncology Group (2013) (4)
- Comprehensive characterization of pediatric acute myeloid leukemia reveals novel molecular features and age-specific interactions (2017) (4)
- Genome Wide Promoter Methylation Patterns Predict AML Subtype Outcomes and Identify Novel Pathways Characterizing Diagnostic and Relapsed Disease in Children (2012) (4)
- Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation (2019) (4)
- Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421 (2010) (4)
- Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG (2020) (4)
- Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia (2016) (4)
- Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative (2012) (4)
- Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group (2016) (4)
- Molecular genetics in children, adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia (2012) (4)
- A Phase 2 Trial of KIR Mismatched Unrelated Donor Transplantation Using In Vivo T-cell Depletion with ATG in AML: Children's Oncology Group AAML05P1 Study. (2019) (4)
- High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group (2010) (4)
- Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. (2020) (4)
- Children's Mercy Kansas City (2020) (4)
- Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis (2020) (4)
- In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia (2019) (4)
- Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. (2018) (4)
- Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group (2016) (4)
- Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration (2016) (4)
- Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group (2021) (4)
- Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group (2021) (3)
- Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies (2021) (3)
- Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative (2015) (3)
- CREBBP Alterations are Associated with A Poor Prognosis in de novo AML. (2021) (3)
- Abstract LB-93: Demonstration of significant clonal evolution from diagnosis to relapse in childhood AML determined by exome capture sequencing: an NCI/COG TARGET AML study (2012) (3)
- Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531 (2015) (3)
- Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia (2021) (3)
- Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission (2013) (3)
- Gene Conversion Is a Late Event in Evolution of High Risk AML. (2007) (3)
- Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group (2013) (3)
- Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML (2013) (3)
- Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631 (2015) (3)
- The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia (2016) (3)
- Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment (2020) (3)
- Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (2018) (3)
- All-Trans-Retinoic Acid (ATRA) Causes Extensive Differentiation In the NPM Mutant, Non-APL Leukemic Cell Line OCI-AML3 (2010) (3)
- Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia (2020) (3)
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML (2020) (3)
- Multimerin-1 ( MMRN 1 ) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia : A Report from the Children ' s Oncology Group (2015) (3)
- The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group (2010) (3)
- Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia (2020) (3)
- Biology of Acute Myeloid Leukemia (2011) (3)
- Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. (2015) (3)
- Novel Method to Perform Functional Drug Screens on Frozen Primary Leukemia Samples (2015) (3)
- Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report (2013) (3)
- Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group. (2019) (2)
- Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML) (2012) (2)
- CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative (2015) (2)
- Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy, (2011) (2)
- Evidence that removal of an endogenous metal that stabilizes the untransformed glucocorticoid receptor in cytosol allows ligand-independent receptor transformation. (1989) (2)
- High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. (2010) (2)
- Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial (2014) (2)
- CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group. (2010) (2)
- A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials (2022) (2)
- Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (2)
- PIM3-SCO2 Fusion Is a Novel Transcription-Induced Chimera That Is Highly Prevalent In Childhood AML (2013) (2)
- Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group. (2009) (2)
- Augmentation of Sensitivity of FLT3/ITD Assay Allows Detection of Minimal Residual Disease In Stem Cell Transplant Recipients-Correlation with Flow Cytometric MRD Assessment (2010) (2)
- Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia (2022) (2)
- Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG (2011) (2)
- Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis (2022) (2)
- CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target (2022) (2)
- Comprehensive characterization of pediatric AML reveals diverse fusion oncoproteins and age-specific mutational interactions (2017) (2)
- Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study. (2006) (2)
- Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access (2020) (2)
- CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes (2021) (2)
- A B-cell developmental gene regulatory network is activated in infant AML (2021) (2)
- Biology and Therapeutic Implications of Genomic Variants (2015) (2)
- Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2006) (2)
- adolescents: recommendations from an international expert panel Diagnosis and management of acute myeloid leukemia in children and (2013) (2)
- Allelic ratio: a marker of clonal dominance. (2014) (2)
- Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML (2018) (2)
- CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia (2019) (2)
- Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration (2016) (2)
- Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group. (2012) (2)
- Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results, (2011) (2)
- CEBPA Mutations Predict Favorable Prognosis in Pediatric AML (2008) (2)
- CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia (2019) (2)
- Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group (2021) (2)
- Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol (2020) (2)
- Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group (2012) (1)
- Identifying Leukemia-Specific Neoepitopes from Next-Generation Sequencing Data to Develop Targeted Immunotherapy for Pediatric Acute Myeloid Leukemiaig (2016) (1)
- Generation of CAR-NK Cells Using a Notch-Mediated Cell Expansion and Differentiation Platform (2020) (1)
- The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group (2016) (1)
- NUP98-KDM5A Fusion Gene Is Not Exclusive to Acute Megakaryoblastic Leukemia and Is an Independent Predictor of Poor Prognosis (2017) (1)
- Clonal Involvement of the CD34+CD33− Progenitor Population by Leukemic Cells Harboring FLT3/ITD Correlates with High Risk of Relapse in Pediatric Acute Myeloid Leukemia. (2005) (1)
- Clonal Involvement of the CD34+CD33− Progenitor Population by Leukemic Cells Harboring FLT3/ITD Correlates with High Risk of Relapse in Pediatric Acute Myeloid Leukemia. (2005) (1)
- Clonal Involvement of the CD34+CD33− Progenitor Population by Leukemic Cells Harboring FLT3/ITD Correlates with High Risk of Relapse in Pediatric Acute Myeloid Leukemia. (2005) (1)
- FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. (2004) (1)
- Characteristics and Prognostic Effects of DNMT3A Co-Mutations (2022) (1)
- RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group. (2009) (1)
- Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group, (2011) (1)
- Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL (2021) (1)
- Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative (2015) (1)
- Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG, (2011) (1)
- Target-Informed Repurposing of Immunotherapies in AML - a Transcriptome Based Approach for Identifying Immediately Available Therapeutics (2020) (1)
- Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia - a COG and Tpaml Study (2019) (1)
- Sequential Acquisition of Somatic Mutations In Progenitors with Differential Proliferative Potential In Human Acute Myeloid Leukemia (2010) (1)
- FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report (2011) (1)
- Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate (2021) (1)
- The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin (2021) (1)
- An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children’s Oncology Group Protocols AAML0531 and 03P1 and St Jude Children’s Research Hospital Protocol AML02 (2014) (1)
- ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin (2018) (1)
- Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group (2010) (1)
- Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531 (2014) (1)
- Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. (2022) (1)
- A JAK/STAT-MEDIATED INFLAMMATORY SIGNALING CASCADE DRIVES ONCOGENESIS IN AF10-REARRANGED AML. (2021) (1)
- ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications (2021) (1)
- Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study (2010) (1)
- Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative (2016) (1)
- WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group (2012) (1)
- Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group (2010) (1)
- The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia (2013) (1)
- Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics (2019) (1)
- Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity (2019) (1)
- CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformation (2021) (1)
- Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy (2020) (1)
- Genomic subtyping and therapeutic targeting of acute erythroleukemia (2019) (1)
- Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes (2022) (1)
- Childhood, adolescent and young adult acute myeloid leukemias (2012) (1)
- Chapter 17 – Acute Myeloid Leukemia (2014) (1)
- Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 (2015) (1)
- FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial (2016) (1)
- SP 126 FLT3 is a stratification factor for targeted therapy treatments in adult and pediatric AML phase III trials (2011) (1)
- Distinct age-associated genomic profiles in acute myeloid leukemia (AML) using FoundationOne heme. (2016) (1)
- Functional miRNA Expression Library Screen Identifies miRNAs That Alter Proliferation and Differentiation in Acute Myeloid Leukemia (2014) (1)
- Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. (2017) (1)
- Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia (2022) (1)
- Targeting PRAME with TCR-Mimic CAR T Cells in AML (2021) (1)
- Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3/ITD Acute Myeloid Leukemia (2018) (1)
- AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. (2022) (1)
- Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA (2021) (1)
- Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium (2018) (1)
- Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia (2017) (1)
- Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia (2015) (1)
- Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients. (2010) (1)
- KDM7A Is Targeted By MiR-155 in Acute Myeloid Leukemia and Impacts Differentiation (2015) (1)
- FLT3 Mutations Are Prevalent and Are Significantly Associated with Induction Death In Pediatric Acute Promyelocytic Leukemia, a Report From the Children's Oncology Group (2010) (1)
- ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative (2015) (1)
- Single Cell Transcriptome Analysis Reveals Changing Levels and Distributions of Stemness across Disease States in Pediatric AML (2017) (1)
- Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 (2018) (1)
- Prevalence and Prognostic Implications of CEBPα Mutations in Pediatric AML. (2007) (1)
- Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation (2022) (1)
- Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALK fus) in Monosomy7 AML (2021) (1)
- RNAIndel: a machine-learning framework for discovery of somatic coding indels using tumor RNA-Seq data (2019) (1)
- Integrative Analysis of Single-Cell RNA-Seq and ATAC-Seq Data across Treatment Time Points in Pediatric AML (2020) (1)
- Abstract 2870: Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia (2019) (1)
- Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis (2017) (1)
- Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor Natural Killer Cell Therapy in Acute Myeloid Leukemia (2021) (1)
- Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia (2023) (0)
- Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup (2022) (0)
- Selective Pressure from Chemotherapy Drives Convergent Evolution in Relapsing and Refractory AML across Age Groups (2018) (0)
- the Children's Oncology Group Ethnicity and survival in childhood acute myeloid leukemia: a report from (2013) (0)
- Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation (2014) (0)
- The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy (2016) (0)
- High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2015) (0)
- The incidence and clinical significance of nucleophosmin mutations in (2013) (0)
- Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients (2021) (0)
- Abstract 3479: UBTF tandem duplications (UBTF-TD) in childhood AML: Enrichment in FLT3-ITD and association with clinical outcome (2022) (0)
- Abstract 1921: TheDDB2intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial (2020) (0)
- Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin (2021) (0)
- Abstract A009: Longitudinal monitoring of pediatric acute myeloid leukemia using duplex sequencing of patient-specific panels reveals ultra-low frequency MRD that marks persistent carcinogenesis and complex clonal evolution (2022) (0)
- Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS^ (2021) (0)
- Abstract 3004: Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project (2017) (0)
- Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group. (2012) (0)
- Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report (2019) (0)
- Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia: A report from the TARGET initiative (2018) (0)
- Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML (2022) (0)
- Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities (2013) (0)
- DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report, (2011) (0)
- Mutation profiling and prediction of outcome in acute myeloid leukemia (2014) (0)
- Duration Of Neutropenia Is Associated With Reduced Relapse Risk In Children With De Novo Acute Myeloid Leukemia: A Report From The Children’s Oncology Group (2013) (0)
- AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (0)
- TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative (2015) (0)
- A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531 (2015) (0)
- NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG (2013) (0)
- Molecular Oncology: FMS-related tyrosine kinase 3 (2013) (0)
- Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate (2022) (0)
- ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial (2019) (0)
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors (2021) (0)
- The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group (2011) (0)
- The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG) (2011) (0)
- Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Children’s Oncology Group (2014) (0)
- Single Cell Sequencing of Pediatric Acute Myeloid Leukemia Reveals Clonal Evolution to Relapse on Combination Chemotherapy with Sorafenib (2021) (0)
- Group acute myeloid leukemia (AML): a report from the Children's Oncology Prevalence and prognostic implications of WT1 mutations in pediatric (2013) (0)
- RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. (2020) (0)
- Abstract 1: Novel pediatric AML patient risk stratification by inferred protein activity through integrative network analysis and machine learning (2021) (0)
- Calcitonin A Genotype Is Associated with Risk of Acute Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation for Children with Acute Myeloid Leukemia in First Remission. (2005) (0)
- Gemtuzumab ozogamycin (GO) and toxic mortality (TM) in children and adolescents with acute myeloid leukemia (AML) enrolled on Children’s Oncology Group (COG) trial AAML0531. (2015) (0)
- Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031 (2017) (0)
- Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions (2021) (0)
- A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. (2012) (0)
- Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group (2012) (0)
- Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion (2021) (0)
- resistance leukemia: prognostic significance and relation to cellular drug FLT3 internal tandem duplication in 234 children with acute myeloid (2013) (0)
- High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia (2022) (0)
- FLT3,RAS, andTP53mutations in elderly patients with acute myeloid leukemia (2001) (0)
- Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor (2022) (0)
- Single-Cell Transcriptomics for Residual Disease Detection in Acute Myelogenous Leukemia Post Allogeneic Hematopoietic Cell Transplantation (2021) (0)
- Biology and Clinical Implications of Complex Landscape of Cooperating Events in FLT3-ITD Acute Myeloid Leukemia (2021) (0)
- Abstract 2289: Empowering point-and-click genomic analysis with large pediatric genomic reference data on St. Jude Cloud (2021) (0)
- MYELOID NEOPLASIA Recurrent abnormalities can be used for risk group strati fi cation in pediatric AMKL: a retrospective intergroup study (2016) (0)
- The Role of Notch in Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy (2018) (0)
- Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531 (2010) (0)
- CSF3R Mutations Synergize with CEBPA and SETBP1 Mutations in Acute Myeloid Leukemia and Chronic Neutrophilic Leukemia (2017) (0)
- Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms (2019) (0)
- Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group (2014) (0)
- Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2014) (0)
- A Prospective Phase 2 Clinical Trial of KIR Mismatched Unrelated Donor Transplantation for Children and Young Adults with High Risk AML: A Report of Children's Oncology Group AAML05P1 Study (2017) (0)
- Outcomes Based on CNS Disease Status in Pediatric Acute Myeloid Leukemia and the Role of Peripheral Blood Contamination in Diagnostic Lumbar Punctures; A Report from the Children's Oncology Group Studies AAML0531 and AAML1031 (2017) (0)
- Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts (2020) (0)
- Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG (2021) (0)
- RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia (2012) (0)
- Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways (2019) (0)
- CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study (2016) (0)
- Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication (2023) (0)
- A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia (2016) (0)
- Abstract P143: Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia (2021) (0)
- Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group (2023) (0)
- Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. (2023) (0)
- Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients (2011) (0)
- Integrative Network Analysis of Pediatric AML Whole Genomes, cDNA Expression and Clinical Data Elements Reveals Shared As Well As t(8;21), Inv16 and MLL Specific Pathways; A Report From COG/NCI Target AML Initiative (2012) (0)
- Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML. (2012) (0)
- Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute (2022) (0)
- Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant (2021) (0)
- 1144 POSTER Using Single-cell Network Profiling (SCNP) Signatures to Predict Response to Induction Therapy and Relapse Risk in Pediatric Patients With Acute Myeloid Leukemia (AML) (2011) (0)
- A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia (2013) (0)
- Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies (2019) (0)
- Genomics of primary chemoresistance and remission induction failure in pediatric and adult acute myeloid leukemia (2016) (0)
- Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report (2021) (0)
- Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia (2021) (0)
- Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. (2023) (0)
- Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols. (2007) (0)
- CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol (2022) (0)
- Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial (2022) (0)
- Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML (2022) (0)
- Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia (2018) (0)
- The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (0)
- Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia (2015) (0)
- Methylation Regulates Expression of Novel Splice Variant and Wild Type Transcripts of IRF8. (2010) (0)
- Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group (2013) (0)
- Time to reconsider CD33 SNP for gemtuzumab response. (2021) (0)
- Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML. (2007) (0)
- SAMHD1 Single Nucleotide Polymorphisms Impact Outcome in Children with Newly Diagnosed Acute Myeloid Leukemia. (2023) (0)
- Abstract LB077: Analysis of indel and structural variant error profiles in deep next generation sequencing data (2023) (0)
- Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study (2022) (0)
- High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group. (2009) (0)
- Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia (2022) (0)
- KMT2A Partial Tandem Duplications (KMT2A-PTD) Is a Rare, but Recurrent Genomic Event in Childhood AML and Associated with High Rate of Co-Occurring FLT3 Mutations (2021) (0)
- Metabolomic Profiling Defines Distinct Metabolic Signature Associated with FLT3/ITD AML (2016) (0)
- Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients (2023) (0)
- Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group (2016) (0)
- Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative (2015) (0)
- Abstract P166: The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-directed gemtuzumab ozogamicin (2021) (0)
- Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia (2019) (0)
- Integrative genomics identifies lncRNA regulatory networks across 1,044 pediatric leukemias and extra-cranial solid tumors (2020) (0)
- TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group (2011) (0)
- Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group. (2012) (0)
- KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report (2011) (0)
- Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML (2022) (0)
- Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned (2017) (0)
- A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML (2017) (0)
- Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia (2016) (0)
- Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531 (2015) (0)
- A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML (2022) (0)
- An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes (2020) (0)
- Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia (2016) (0)
- Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (2019) (0)
- Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML (2016) (0)
- Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML (2016) (0)
- Transcriptome Analysis of Pediatric AML Reveals Non Protein-Coding RNAs Associated with Poor Survival Outcome and Treatment Resistance (2019) (0)
- Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML (2021) (0)
- Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. (2022) (0)
- Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106 (2015) (0)
- Coordinate Changes In RNA Expression, Transcript Splicing, and DNA Methylation In Pediatric AML (2013) (0)
- Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2016) (0)
- Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML (2016) (0)
- A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies (2019) (0)
- Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML (2020) (0)
- A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome (2019) (0)
- CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics (2018) (0)
- Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML (2021) (0)
- Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML (2021) (0)
- Single Cell Molecular Genotyping Reveals Significant Molecular Heterogeneity at Diagnosis and Emergence of Clonal Dominance at Relapse (2008) (0)
- Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report (2016) (0)
- Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML. (2012) (0)
- Characterization Of FLT3/ITD Resistant Cells and Identification Of Novel Therapeutic Targets Utilizing High Throughput Drug Screening (2013) (0)
- Abstract 3028: Integrative genomics reveals lncRNAs associated with pediatric cancer (2021) (0)
- High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group. (2012) (0)
- Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia (2020) (0)
- Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML (2018) (0)
- T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML (2021) (0)
- Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin (2019) (0)
- Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML) (2012) (0)
- EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (FUS-ERG) (2021) (0)
- Abstract 5583: Integrative genomic analyses on pediatric acute myeloid leukemia (2014) (0)
- Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia (2017) (0)
- Integrated Transcriptomics and Proteomics Identifies Therapeutic Targets in Pediatric Acute Myeloid Leukemia (2021) (0)
- Abstract 1075: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C’Dot-drug-conjugate (2022) (0)
- Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML (2019) (0)
- Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. (2023) (0)
- The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia (2020) (0)
- Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. (2023) (0)
- 12-1-2016 miR-155 expression and correlation with clinical outcome in pediatric AML : A report from Children ' s Oncology Group . (2019) (0)
- The Transcriptomic Landscape of NUP98-Rearranged Pediatric Acute Myeloid Leukemia (2020) (0)
- Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study (2015) (0)
- DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components (2023) (0)
- Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78 (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Soheil Meshinchi?
Soheil Meshinchi is affiliated with the following schools:
